Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PANCRELIPASE EQUIVALENT TO LIPASE & AMYLASE & PROTEASE

All products: Limited Use (codes 124, 125, 126, 225)

Other products in the same Health Canada class (A09AA) — coverage varies; not interchangeable

  • Amylase + lipase + protease (Creon Minimicrospheres 35): limited Use 124, 125, 126, 225

Creon Minimicrospheres Micro · DIN 02445158 · 5100 & 500 & 320 Units/100mg · Gran - 100mg/Scoop

Limited Use — Reason for Use code 124, 125, 126, 225 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 124, 125, 126, 225 required
Write on scriptLU code 124, 125, 126, 225 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 124, 125, 126, 225
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 225 Replacement therapy for pancreatic insufficiency due to cystic fibrosis. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Creon Minimicrospheres Micro · DIN 02445158 Manufacturer: BGP Pharma ULC; listing date 2017-04-27 Health Canada: Marketed since 2015-11-18 · brand CREON MINIMICROSPHERES MICRO · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Granules for suspension (delayed-release · route Oral · ingredients AMYLASE 5100 UNIT/100MG, LIPASE 5000 UNIT/100MG, PROTEASE 320 UNIT/100MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Creon Minimicrospheres Micro: Formulary list price $0.1912/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1912 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93037 · Verify on the e-Formulary ↗ (DIN 02445158)

Source record
DIN 02445158: Creon Minimicrospheres Micro Raw flags: sec12=Y, sec3=Y Item: 561600056; group id 660; item number 1647; lccId 00097; manufacturer id BGP Source form: Gran - 100mg/Scoop; strength: 5100 & 500 & 320 Units/100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.1912; ministry $0.1912 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02445158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93037
Shortage status: resolved shortage (ended 2026-03-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02445158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:16 Digestants) and how they are covered

Matched class: 56:16 Digestants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 56:16 Digestants

LIPASE & AMYLASE & PROTEASE

· 1 products · Limited Use, codes 124, 125, 126, 225 · strengths: 35000 & 35700 & 2240 Units · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:16
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE COTAZYM® (pancreatic enzymes) is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy. Geriatrics (> 65 years of age): Clinical studies of COTAZYM® in geriatric patients have not been conducted. Pediatrics (<18 years of age): Post approval, several clinical studies have been conducted supporting the safe and effective use of COTAZYM® in pediatric patients with established pancreatic insufficiency. https://pdf.hres.ca/dpd_pm/00060547.PDF PM date: March 30, 2021 Source product: COTAZYM; DIN 00263818; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.